Bionano Genomics, Inc.
Close on Oct 19, 2026
- Market cap
- $14.09M
- P/E (TTM)
- –
- Dividend yield
- –
About Bionano Genomics
Laboratory Analytical Instruments, SIC 3826
Bionano Genomics, Inc. is a life sciences company that provides optical genome mapping solutions for genomic analysis and cytogenetic research. The company offers imaging instruments, notably the Saphyr and Stratys systems, along with related consumables, testing services, and VIA data analysis software. It conducts business through a single reportable segment and operates subsidiaries including BioDiscovery, Purigen Biosystems, and Lineagen, which operates as Bionano Laboratories. Its customers include researchers, cytogeneticists, and laboratories performing routine genomic analysis.
The company’s principal executive offices are located in San Diego, California, with additional facility operations in Pleasanton, California. Geographically, Bionano serves customers and delivers products across three primary regions: the Americas, Asia-Pacific, and Europe, the Middle East, and Africa. Its global operations rely on domestic and international sales channels alongside contract manufacturing partners and suppliers.
Summary of the business section of Bionano Genomics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Bionano Genomics, Inc.
- Headquarters
- San Diego, CA
- Address
- 9540 Towne Centre Drive, Suite 100 92121
- Phone
- (858) 888-7600
- Employees
- 97, Dec 31, 2025
- Industry
- Laboratory Analytical Instruments
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C., San Diego, California
Stock & identifiers
- Ticker
- BNGO
- Exchange
- Nasdaq
- IPO date
- Aug 22, 2018
- Shares outstanding
- 12M, Aug 6, 2026
- Public float
- $12.15M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-60 reverse, Jan 27, 2025; 1-for-60 reverse, Jan 15, 2025; 1-for-10 reverse, Aug 7, 2023; 1-for-10 reverse, Aug 4, 2023
- SEC CIK
- 1411690
- CUSIP
- 09075F404
- ISIN
- US09075F4046
- LEI
- 54930086AP7ROH0VJ631
- EIN
- 26-1756290
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Albert Luderer | Interim Chief Executive, Director | 8,000 |
| R. Erik Holmlin | PRESIDENT AND CEO, Director | 1,665 |
| Jonathan V. Dixon | General Counsel | 239 |
| Mark Adamchak | Principal Accounting Officer | 253 |
| Alex Reid Hastie | Chief Scientific Officer | 63 |
| Mark Oldakowski | Chief Operating Officer | 868 |
| Alka Chaubey | CHIEF MEDICAL OFFICER | 620 |
| Aleksandar Rajkovic | Director | 0 |
| Kristiina Vuori MD | Director | 0 |
| Christopher J. Twomey | Director | 74,500 |
| David L. Barker | Director | 58,364 |
| Yvonne Linney | Director | 0 |
| Hannah Mamuszka | Director | 65,789 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 R. Erik Holmlin, Ph.D | $1.11M | $1.01M | $756.33K | $0 | – |
| FY2024 R. Erik Holmlin, Ph.D | $989.68K | $535.44K | $662.64K | $2 | – |
| FY2023 R. Erik Holmlin, Ph.D | $1.53M | -$949.35K | $1.03M | $13 | – |
| FY2022 R. Erik Holmlin, Ph.D. | $2.77M | $740.06K | $4.72M | $48 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of 97 employees, 95 of whom were full-time employees and 2 of whom were part-time employees.”
Corporate history
Events identified from SEC filings